Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Urogenital Neoplasms × Lutetium × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urogenital Neoplasms 1 Prostatic Neoplasms 1 Prostatic Diseases 1

Interventions

Abiraterone Acetate 2 vedolizumab 1 tislelizumab 1 onapristone 1 olaparib 1 abiraterone 1 Pluvicto 1 Neoadjuvant Therapy 1 Lutetium-177 1 Lutetium 1 LDP-02 1 Infliximab 1 Immunoglobulin G 1 Docetaxel 1 Disulfides 1 CT-P13 1 BAY 86-7548 1 Androgen Antagonists 1 Adrenal Cortex Hormones 1 Administration, Intravesical 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05413850 2026-03-02

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

Blue Earth Therapeutics Ltd

Phase 1/2 Recruiting

Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡